CTOs on the Move

ENABLE Healthcare Communications

www.enablehealthcare.com

 
ENABLE Healthcare Communications is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Turnpaugh Health and Wellness Center

Turnpaugh Health and Wellness Center is a healthcare center that takes a whole body approach to health and wellness care, incorporating physical medicine, nutrition, emotional health, and ongoing support.

Drake-Scruggs Equipment Inc

Drake-Scruggs Equipment Inc is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mercy Care Plan

At Mercy Healthcare Group we are committed to serving the needs of small businesses. Whether you are self-employed, an independent contractor, or a small employer with up to 50 employees, we can provide health care coverage for you, your employees and

Health Benefit Service Administrators (HSBA)

Health Benefit Service Administrators (HSBA) is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.